

The Essential Biodata Life Science Partner in Rare and Neurodegenerative Diseases

CENTOGENE (CNTG) Company Presentation
May 2022



Disclaimer

This presentation has been prepared by CENTOGENE N.V. (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology, such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, such as negative economic and geopolitical conditions and instability and volatility in the worldwide financial markets, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.

For further information, please refer to the Risk Factors section in our Annual Report for the year ended December 31, 2020, on Form 20-F filed with the SEC on March 31, 2022, and other current reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

CENTOGENE @ a glance




- Headquarters **Rostock, Germany** with locations in **Boston, MA, Berlin, Germany,** and **Rotkreuz, Switzerland**
- **~500 employees**
- Listed on **Nasdaq** in November 2019 (Ticker: CNTG)



- **2021 Core Business revenues €43.5 million**
- Guidance 2022:
 - **Total revenues €68 - €70 million**
 - **Core Business revenues ~ €50 - €52 million** (YoY growth 15-20%)



- **CENTOGENE Biodatabank**, the **world's largest real-world data repository** for rare and neurodegenerative diseases
- State-of-the-art **genomics and multiomics reference lab** (ISO, CAP, & CLIA certified)



- **>50 collaborations with biotech/biopharma partners**, covering over **46 rare diseases**
- **Market access and expansion, clinical development, target and drug screening**

Our leadership team combines a blend of commercial and scientific excellence



Kim Stratton
Chief Executive Officer

- Joined 2021
- 30+ years experience in pharma
- Board of Recordati S.p.A, Novozymes A/S and Vifor Pharma AG



Miguel Coego
Chief Financial Officer (ai)

- Joined 2022
- 15+ years of finance and commercial experience



Prof. Peter Bauer, M.D.
Chief Genomic Officer

- Joined 2016
- Expert in rare diseases genetics
- 140+ publications
- Instrumental in building up Biodatabank
- VP German Society of Neurogenetics



Bettina Goerner
Chief Data Officer

- Joined 2021
- 15 years experience at intersection of data, technology, and science
- Advisory Board Member at Deepmatter, Eagle Genomics, and PhagoMed Biopharma



Maximilian Schmid, M.D.
Chief Commercial Officer

- Joined 2021
- 20+ years of experience in Europe, U.S., and APAC
- Habilitation in prenatal genetics



Patrice Denèfle, Ph.D.
Chief Scientific Officer

- Joined 2021
- 35+ years leadership experience biotech and pharma
- Biotechnology & biotherapeutics, incl. genetic therapies, molecular and clinical pharmacology, translational research, and precision medicine

ORPHA Z YME



NOVARTIS



ORPHA Z YME



EBERHARD KARLS
UNIVERSITÄT
TÜBINGEN



SPRINGER NATURE

eagle
genomics



McKinsey
& Company

Ariosa
DIAGNOSTICS



MEDICAL UNIVERSITY
OF VIENNA

IPSEN
Innovation for patient care



GENETHON
CURE THROUGH INNOVATION

4P-Pharma
Translating Science
to Product

News flow and outlook

2021 Year end highlights

Company

- Core Business ~40€ million; Single digit growth
- Announced phase-out of COVID-19 business after ~250€ million revenues since 2020

Dx & CENTOGENE Biodatabank

- Launch of NEW CentoXome enhanced WES
- CENTOGENE Biodatabank >650,000 individuals
- Twist Bioscience partnership to develop custom assay kits for rare diseases

Biopharma Partnerships

- Takeda: Partnership extension for genetic disorders
- Agios: Partnership expansion for rare blood diseases
- Alector: 1st patient enrolled in FTD study
- Denali: 10,000+ patients in global Parkinson's study

Q1

- ✓ Leadership team in place
- ✓ ~\$62 million financing, addressed going concern
- ✓ Close of COVID-19 business
- ✓ Launched CentoCloud® Globally
- ✓ Insilico Medicine collaboration on orphan drug development for Niemann-Pick type C

- ✓ Pfizer: Continued Data Access & Collaboration Agreement for discovery & validation of novel genetic targets

2022

- 15-20% Core Business revenues growth, overall topline revenues of 68-70€ million
- Return to growth in Pharma with focus on commercial execution

- Launch CentoCloud 2.0 & kit in collaboration with TWIST
- Publication on CentoMetabolic efficacy

- ✓ Secured contract extension with largest pharma partner
- Publication on NPC cohort and biomarker efficacy
- Disease avatars for NPC, Gaucher, GPD

Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Fueling revenues, growing CENTOGENE Biodatabank, and building biopharma partnerships

3 STRATEGIC PILLARS

1 DIAGNOSTICS

Highly differentiated testing portfolio

Easy logistics via CentoCard & CentoCloud

WES/WGS

Multiomics

Network of ~29,000 active physicians

2 CENTOGENE BIODATABANK

Fuel CENTOGENE Biodatabank with biomaterial, multiomics, as well as clinical data

Productize Bio/Databank (data monetization)

3 BIOPHARMA PARTNERSHIPS

MARKET ACCESS & EXPANSION

Real world Registry

Early Access Programs

Patient Stratification, Genetic & Biomarker Profiling, Modelling

Patient Identification & Diagnostics

CLINICAL DEVELOPMENT

Observational Studies (e.g., epidemiology, patient finding, genetic & biomarker profiling)

POC/ Ph II/III:

Patient Multiomic Profiling, Stratification, Modelling, Efficacy Marker

Patient Identification & Diagnostic


TARGET & DRUG SCREENING

Patient-derived Cell Models & Multiomics

Biomarker/ Assay Identification & Validation

CENTOGENE BIODATA NETWORK (Insight Reports & Biodata licenses)

CENTOGENE Biodatabank: the world's largest real-world data repository for rare and neurodegenerative diseases



CENTOGENE Pharma Product List - Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Target & Drug Screening

Patient-derived
Cell Models &
Multiomics

Biomarker/Assay
Identification &
Validation

Clinical Development

Observational Studies

POC/ Ph II/III

Observational
Studies
(e.g., epidemiology,
patient finding,
genetic & biomarker
profiling)

Patient Multiomic
Profiling,
Stratification,
Modelling,
Efficacy Marker

Patient
Identification &
Diagnostics

Market Access & Expansion

RW Registry &
Early Access
Programs

Patient
Stratification,
Genetic &
Biomarker Profiling,
Modelling

Patient ID &
Diagnostics

CENTOGENE Biodata Network

Insight Reports
(e.g., new and existing reports, clinical,
genetic, epidemiology)

Biodata Licenses

Biopharma strategy: Our ambition is to be the essential biodata life science partner in rare and neurodegenerative diseases

Market Access and Expansion



- Real world registry
- Early access programs
- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling
- Patient Identification
- Patient Diagnostics

Clinical Development



Observational studies

- Epidemiology
- Patient finding
- Genetic and biomarker profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification
- Modelling
- Efficacy markers

Target & Drug Screening



- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network



- Insight Reports (e.g., new and existing reports, clinical, genetic, epidemiology)
- Biodata Licenses



Market access and expansion: maximize access and personalise patient, provider and biopharma value

Market Access and Expansion



- Real world registry
- Early access programs
- Patient Stratification
- Genetic and Biomarker Profiling
- Modelling
- Patient Identification
- Patient Diagnostics
- CENTOGENE Biodata Network
 - Insight Reports & Biodata Licenses



- **2015 - Ongoing**
- **Rare Metabolic and Rare Neurodegenerative Diseases**
- **Provide diagnostic testing services** to identify patients with **rare metabolic and rare neurodegenerative diseases**
- **42 Countries**



- **2015 - Ongoing**
- **Hereditary transthyretin amyloidosis (hATTR) disease**
- **Sponsored testing program** with > 600 samples from 10 countries (Europe) & 125 samples (U.S.)



- **2019 - Ongoing**
- **Duchenne muscular dystrophy (DMD)**
- **DMD Sponsored testing program (250 samples)**
- **5 countries:** UAE, KSA, Lebanon, Kuwait, Egypt



- **2019 - Ongoing**
- Identify patients in **DMD & Aromatic L-amino Acid Decarboxylase (AADC)**
- **Genetic testing and biomarker analytics** for AADC deficiency in **65 countries** (LATAM, Europe, MENA)
- **>2500 DMD & >2900 AADC samples screened**

Clinical development: accelerate and expand biopharma partnerships

Clinical Development



Observational studies

- Epidemiology & Patient finding
- Genetic & biomarker profiling

POC/Ph II/III

- Patient multiomic profiling
- Stratification, Modelling, and Efficacy markers
- Patient identification & diagnostics

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses



- **2021**
- **Hypophosphatasia (HPP)**
- Strensiq (innovative enzyme replacement therapy)
- **De novo variant identification** for HPP and **identification of potential new genes** causing HPP
- **Germany**



- **2021 - Ongoing**
- **Pyruvate kinase ("PK") deficiency**
- **Genetic testing and identification of causative mutations**, incl. HBA1, HBA2, and HBB genes, in Ph. II/III trials
- **20 Countries** (North America, Europe, MENA, APAC, & LATAM)



- **2018 - Ongoing** (ROPAD 1 & 2 Study with extensions)
- **Parkinson's disease (PD)**
- **Enroll and genotype 12,500 patients**
- **10 countries**
- Success milestone: **10,000 patients enrolled and genotyped**



- **2020 - Ongoing**
- **Hereditary transthyretin-related amyloidosis (hATTR)**
- **Longitudinal study providing a molecular genetic diagnosis of hATTR** via NGS and MLPA
- **Germany**
- **5,000 patients enrolled**



- **2018 - 2021**
- **Gaucher disease**
- **Longitudinal natural history study** (LysoProof) with **>1,600 samples analyzed**
- **13 countries** (EU, LATAM, APAC, MENA)
- **Identified and genetically tested >250 Gaucher patients**



- **2021 - Ongoing**
- **Frontotemporal dementia (FTD)**
- **Enroll and genetically test over 3,000 FTD patients in EFRONT Study**
- **7 countries** (Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey)

Target & drug screening: build partnerships around precision and confidence

Target and Drug Screening



Target & Drug Screening

- Patient-derived cell models & multiomics
- Biomarker/Assay identification & validation

CENTOGENE Biodata Network

- Insight Reports & Biodata Licenses



- **2021 - Ongoing**
- **Niemann-Pick type C**
- **Collaboration to generate data set to enable start of drug discovery**



- **2020 - Ongoing**
- **Gaucher Disease – joint drug discovery project**
- **Joint drug discovery project to identify small molecules reducing biomarker Lyso-GB1 in disease cell models**
- **Transcriptomic and metabolomic data set enabling patient selection with highest unmet need**




- **2021 - Ongoing**
- **Friedreich's Ataxia, Duchenne Muscular Dystrophy, Hereditary transthyretin-related amyloidosis**
- **Novel biomarker discovery to stratify and monitor patients for disease severity/progression and to enable the discovery of disease modifiers explaining heterogeneity**




- **2018 - Ongoing**
- **Rare neurodegenerative diseases**
- **Data Access and Collaboration Agreement granting access to CENTOGENE's Biodatabank for discovery & validation of novel genetic and biochemical targets for the potential development of new therapies for rare diseases**

We are an essential partner across Biopharma for diagnosing, understanding, and treating rare and neurodegenerative diseases



We have knowledge and learnings from a broad footprint of over 2,500 rare and neurodegenerative diseases to deepen scientific understanding and support development of breakthrough therapies



CENTOGENE's unique Biodatabank: The world's broadest geographic footprint of real-world data to generate meaningful insights


Diverse geographies, ethnicities and patient characteristics:

- Healthy/mild/severe
- Carriers and family members

>400,000 biosamples from
>120 countries

>650,000 individuals
>30,000 via clinical studies

~29,000 active physicians
in our network*



Diversity is key in fully considering varying genetic makeups and differences in treatment efficacy

>2,500 rare diseases diagnosed

>31 million unique variants

~50% of individuals with broad research consent for commercial and academic research

**Clinical
Diagnostics**

**Market Access
& Expansion**

**Clinical
Development Support**

**Target & Drug
Screening**

First-class data capture and proprietary curation and analysis technologies established the CENTOGENE Biodatabank to predict, accelerate, and personalize treatment


Data capture



Central collection and storage of biosamples
from >120 countries



Clinical data capture



Clinical data extraction & curation



Whole genome sequencing




State-of-the-art mass spectrometry



RNA sequencing

Data bioinformatics



Automated pipelines for

- variant annotation
- prioritization
- medical reporting
- > 31 million variants
- multiomic analysis and combination expertise

Data utilization

Clinical Diagnostics

Biopharma Partnerships

Target & Drug Screening

Clinical Development Support

Market Access & Expansion

Value chain supported by advanced bioinformatics and AI tools


Our genetic Parkinson's disease dataset is unique in depth and breadth

Existing data and biomaterial can support work on diagnosis, disease progression, and treatment



~10,500 research consented individuals + Controls

CENTOGENE Biodatabank



Multiomic Data

Whole Genomes, Variants, Biomarker, Enzymatic Activity

Clinical Data

Symptoms (HPO), Medication, History, MDS-UPDRS Neuro Test, Age of Onset

Biomaterial

Dried Blood Spots Cards

Sociodemo-graphic information

Gender, Age, Geography, Ethnicity, Family History

Target & Drug Screening


Clinical Trial Support

Market Access & Expansion


Diagnostics: A distinctive offering and services that support efficient and timely diagnosis of rare and neurodegenerative diseases, leading to better treatment and health outcomes

Highly differentiated testing portfolio in state-of-the-art CLIA/CAP certified laboratory with **deep medical expertise**



Exome testing



Genome testing



Multiomic testing



Easy logistics for centralized testing enabling **broad access to multiomics**



Dry-lab (SaaS) solution enabling laboratories around the world to deliver leading diagnostic **insights to local patients**



Unique global footprint with **network of ~29,000 active physicians** and **focus on countries with a high prevalence of rare diseases**

Partnership and revenues potential: With biotech and biopharma projects and products in rare and neurodegenerative diseases as well as gene therapies

Potential for 100+ partnerships

Discovery

- Growing # of discovery projects across rare and neurodegenerative diseases, incl. gene therapies
- >\$22 billion investment in research for rare disorders in 2021 +28% vs 2020



Clinical development¹

- ~221 Preclinical Programs
- ~414 Ph I
- ~668 Ph II
- ~318 Ph III



In-market products*

- >5,000 orphan drug designations granted by FDA
- 23 FDA approved cell and gene therapies
- 52% of all US approvals in 2021 were orphan drugs

Patient & Market Potential in Rare & Neurodegenerative

Rare disease drug market - total + growth²

Revenue (\$Bn)



~350 million patients³

By 2024, 18% Rx worldwide will be for RD

Neurodegenerative drug market (incl. Parkinson's, Alzheimer)

Revenue (\$Bn)




~1 billion patients⁴

* Based on FDA approvals per Jan. 2022. Sources: 1. Evaluate 2020 + internal management estimates. 2. Evaluate 2020 Orphan Drug market. 3. <https://www.businesswire.com/news/home/20210511005530/en/Global-Neurodegenerative-Drugs-Market-Report-2021-Market-to-Reach-47.8-Billion-by-2027--Parkinsons-Disease-Segment-is-Expected-to-Account-for-15.4-Billion--ResearchAndMarkets.com>. 4. United Nations 2007 (<https://news.un.org/en/story/2007/02/210312-nearly-1-6-worlds-population-suffer-neurological-disorders-un-report>)

CENTOGENE 2021 Financials

Core Business - Dx and Biopharma revenues¹



Record year for Diagnostics

Diagnostics

- Full year 27.9 € million +26% vs FY 2020
- 57,000 test requests +36% vs FY 2020
- WES and WGS ~ 20 € million +25% vs FY 2020


Impacted by COVID

Biopharma


- Full year 15.6 € million -8% vs FY 2020
- Q4 revenues 6.5 € million +40% YoY
- 45 active collaborations by end 2021
- Revenues from new collaborations 2.3 € million, upfront payments 0.5 € million
- Driven by partnerships in patient identification and clinical development

CENTOGENE Financials: 2022 poised for post-COVID recovery and refocus on core business and growth strategy

Core Business - Dx and Biopharma revenues¹



FY 2022 Guidance²



- **\$62 million financing (~€55 million)** announced Q1 2022:
 - €15 million PIPE & \$45 million debt³
- Flat Q1, acceleration in second half driven by biopharma
- Q1 COVID-19 revenues of ~€18 million; exit in **Q1 2022⁴**

CENTOGENE 2022 Priorities: Focus on growth, execution, fit-for-purpose organization



Meet/Exceed Revenues Guidance

- 68-70 € million total revenues
- Core Business: ~50-52 € million (i.e. 15-20% growth)



Fuel Biopharma Partnerships

- Fully execute on our existing 30+ partnerships
- Target ~20+ new pipeline deals



Optimize Dx Revenues Growth

- Focus on profitable growth
- Commercial excellence, CentoCloud & multiomics



Fit-for-Purpose Organization

- Drive fit-for-purpose organization
- Focus on efficient operations and margin improvement

Thank you

To our investors

To our partners

To our associates

MISSION

Together let's cure
100 rare diseases
(and others) in the
next 10 years

